Drug Trial Radar · NCT05184335
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
690
Planned (sponsor's estimate)
Start
Jan 24, 2022
Primary completion
Feb 2025
Study completion Feb 2025
Sponsor
- Lead sponsor
- Reviva PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Conditions
- Schizophrenia
Interventions
BrilaroxazineDrug
RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
PlaceboOther
RP5063 matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Safety and Efficacy of Brilaroxazine (RP5063)Time frame: 28 days
- Open label Safety and Efficacy of Brilaroxazine (RP5063)Time frame: 52 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Reviva site
Phoenix, Arizona · Recruiting
Reviva site
Bentonville, Arkansas · Recruiting
Reviva site
Little Rock, Arkansas · Recruiting
Reviva site
Rogers, Arkansas · Recruiting
Reviva site
Garden Grove, California · Recruiting
Reviva site
Lemon Grove, California · Recruiting
Reviva site
Riverside, California · Recruiting
Reviva site
Hollywood, Florida · Recruiting
Reviva site
Hollywood, Florida · Recruiting
Reviva site
Miami Lakes, Florida · Recruiting
Reviva site
Atlanta, Georgia · Recruiting
Reviva site
Decatur, Georgia · Recruiting
Reviva site
Chicago, Illinois · Recruiting
Reviva site
Gaithersburg, Maryland · Recruiting
Reviva site
Boston, Massachusetts · Recruiting
Reviva site
Oklahoma City, Oklahoma · Recruiting
Reviva site
Austin, Texas · Recruiting
Reviva site
Richardson, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.